INDICATIONS DOSAGE AND ADMINISTRATION
Pizotifen hydrogen malate was evaluated in multiple reproductive and developmental toxicity studies for its effects on fertility and its embryotoxic, fetotoxic, teratogenic and …
Download INDICATIONS DOSAGE AND ADMINISTRATION
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION …
labeling.cslbehring.comFULL PRESCRIBING INFORMATION Helixate® FS Antihemophilic Factor (Recombinant) Formulated with Sucrose 1TIONS AND USAGE INDICA Helixate® FS is a recombinant antihemophilic factor indicated for: • On-demand treatment and control of bleeding episodes in adults and children with
Immune Globulin Intravenous (Human), 10% …
www.abopharmaceuticals.comCSL Behring Immune Globulin Intravenous (Human), 10% Liquid Privigen™ US Package Insert July 2007 Page 2 VERSION 10.0 FULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.products.sanofi-aventis.usaugment hypotension caused by dialysis. Monitor patients for signs and symptoms of hypotension during and following Ferrlecit administration [see Adverse Reactions (6.1)].
DOSAGE FORMS AN - Venofer® (iron sucrose …
www.venofer.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VENOFER safely and effectively. See full prescribing information for VENOFER.
Venofer - Food and Drug Administration
www.accessdata.fda.govNDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)- hydroxide in sucrose for intravenous use. Iron sucrose injection has a molecular weight of
VUMC INTRAVENOUS MEDICATION …
www.mc.vanderbilt.edu* Refer to references such as Mosby’s for additional information on administration and monitoring. Alternate infusion rates permitted at provider discretion.